Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kunitz-type protease inhibitors (KPIs) from the venom of Daboia siamensis (Eastern Russell's Viper) are small, disulfide-rich proteins that play a significant role in the pathophysiology of envenomation (UniProt: P0C221). These toxins function by potently inhibiting serine proteases, including trypsin, plasmin, and various factors within the blood coagulation cascade (PubMed: 25813447). By disrupting the balance of protease activity, they contribute to symptoms such as systemic hemorrhage and coagulopathy, which are hallmarks of Russell's viper bites (NCBI: PMC4141112). In a clinical context, these proteins are the primary targets for neutralization by therapeutic antivenoms, which consist of purified antibodies or antibody fragments (PubMed: 15183871). Beyond their role as toxins, KPIs are studied for their potential as structural templates in drug design due to their high stability and specificity for protease targets (PubMed: 28601615). Effective management of envenomation relies on the rapid administration of antivenom to prevent the irreversible binding of these inhibitors to their physiological targets.
Therapeutic antivenoms contain specific antibodies (IgG or F(ab')2 fragments) that bind to the Kunitz-type inhibitors, sterically hindering their ability to bind and inhibit endogenous serine proteases such as plasmin or coagulation factors (PubMed: 15183871).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kunitz-type serine protease inhibitor (Daboia siamensis) (KPI).